{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AIN457+150+mg",
    "query": {
      "intervention": "AIN457 150 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AIN457+150+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T12:45:35.976Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01406938",
      "title": "Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "AIN457 150mg",
          "type": "DRUG"
        },
        {
          "name": "AIN457 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 967,
      "start_date": "2011-08",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-05-19",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 33,
      "location_summary": "Fresno, California • Pasadena, California • Sacramento, California + 28 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01406938"
    },
    {
      "nct_id": "NCT03769168",
      "title": "An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Juvenile Psoriatic Arthritis",
        "Enthesitis Related Arthritis"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "2 Years to 100 Years"
      },
      "enrollment_count": 55,
      "start_date": "2019-06-07",
      "completion_date": "2024-11-07",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 3,
      "location_summary": "Boise, Idaho • Cincinnati, Ohio • Portland, Oregon",
      "locations": [
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03769168"
    },
    {
      "nct_id": "NCT00995709",
      "title": "Phase III Study in Refractory Behcet's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Behcet Disease"
      ],
      "interventions": [
        {
          "name": "AIN457",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2009-10",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2015-08-31",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Arlington, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00995709"
    },
    {
      "nct_id": "NCT04930094",
      "title": "Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Giant Cell Arteritis (GCA)"
      ],
      "interventions": [
        {
          "name": "Secukinumab 300 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Secukinumab 150 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "50 Years to 100 Years"
      },
      "enrollment_count": 354,
      "start_date": "2021-10-06",
      "completion_date": "2026-02-18",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Plantation, Florida • Sarasota, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04930094"
    },
    {
      "nct_id": "NCT01649375",
      "title": "16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anklyosing Spondylitis"
      ],
      "interventions": [
        {
          "name": "Secukinumab (75 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab (150 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2012-10-18",
      "completion_date": "2018-09-18",
      "has_results": true,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 10,
      "location_summary": "Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        },
        {
          "city": "Tupelo",
          "state": "Mississippi"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01649375"
    },
    {
      "nct_id": "NCT01892436",
      "title": "Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2013-09-30",
      "completion_date": "2018-01-11",
      "has_results": true,
      "last_update_posted_date": "2019-06-12",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 22,
      "location_summary": "Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892436"
    },
    {
      "nct_id": "NCT01544595",
      "title": "Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "Secukinumab (AIN457)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1147,
      "start_date": "2012-06-19",
      "completion_date": "2017-06-26",
      "has_results": true,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01544595"
    },
    {
      "nct_id": "NCT01132612",
      "title": "AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "AIN457",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2010-05-11",
      "completion_date": "2016-10-18",
      "has_results": true,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01132612"
    },
    {
      "nct_id": "NCT01377012",
      "title": "Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Secukinumab (AIN457)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 637,
      "start_date": "2011-08-30",
      "completion_date": "2015-09-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 39,
      "location_summary": "Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01377012"
    },
    {
      "nct_id": "NCT02159053",
      "title": "16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spondylitis, Ankylosing"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2015-05-18",
      "completion_date": "2018-01-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-09-14T12:45:35.976Z",
      "location_count": 12,
      "location_summary": "Anniston, Alabama • Upland, California • Aventura, Florida + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159053"
    }
  ]
}